GleamWall
中文EN

NYMXF NYMOX PHARMACEUTICAL CORP IFRS

In Vitro & In Vivo Diagnostic Substances · OTC · SEC CIK 1018735 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY—
TTM net income YoY49.2%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-701.3%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets1,135.9%
Debt / equity—
Current ratio0.09x
Interest coverage-18.95x

Cash quality & payout

Operating cash flow / net income0.58x
Accruals ratio-295.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20242024-12-31FY20232023-12-31
Income statement
Revenue—$0
Cost of revenue—$0
Gross profit—$0
R&D expense$3.28M$3.99M
SG&A expense$1.00M$4.36M
Operating income-$4.28M-$8.35M
Interest expense$226,000$58,000
Pretax income-$4.49M-$8.84M
Income tax$0$0
Net income-$4.49M-$8.84M
EPS (basic)-0.05-0.10
EPS (diluted)——
Balance sheet
Cash & equivalents$74,000$70,000
Receivables$0$0
Current assets$653,000$625,000
PP&E, netmay include right-of-use assets (IFRS)$1,000$2,000
Total assets$654,000$627,000
Current liabilities$7.43M$3.80M
Total liabilities$7.43M$3.80M
Shareholders' equity-$6.78M-$3.17M
Shares outstanding94.54M93.54M
Cash flow statement
Operating cash flow-$2.60M-$4.06M
Capital expenditure$0$3,000
Free cash flow-$2.60M-$4.06M
Investing cash flow$0-$3,000
Financing cash flow$2.60M$2.73M
Stock-based compensation$671,000$3.36M

Free plan shows the latest 2 periods; Pro shows all 10 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.